Open access

Research Article

18 November 2024

Real-world clinical outcomes and rationale for initiating abatacept as a first-line biologic for patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis

Publication: Journal of Comparative Effectiveness Research

Volume 13, Number 12

https://doi.org/10.57264/cer-2023-0144

PDF OtherFormats

Abstract

Aim: In rheumatoid arthritis (RA), seropositivity for both anticitrullinated protein antibody (ACPA) and rheumatoid factor (RF) is associated with disease severity and therapeutic response. Biologic (b) disease-modifying antirheumatic drugs (DMARDs) such as abatacept are recommended after inadequate response or contraindication to conventional synthetic DMARDs. This retrospective cohort study aimed to describe changes in Clinical Disease Activity Index (CDAI) measures over 12 months among patients with ACPA+ and RF+ RA with an inadequate response to methotrexate treated with abatacept as a first-line bDMARD. Patients & methods: Patient data were abstracted from medical records by treating rheumatologists. Analyses included McNemar tests for paired proportions or paired t-tests to assess longitudinal changes in CDAI scores, and Kaplan–Meier methods for time-to-event outcomes. Serious AEs and rationale for initiating treatment were recorded. Results: Overall, 296 patients were included. Mean CDAI scores improved (decreased) by 34.0, 61.0 and 74.0% (all p < 0.001) from baseline to 3–6 months, 6–12 months and ≥12 months after abatacept initiation, respectively. Of 279 patients not in CDAI low disease activity (LDA) or remission at baseline, 24.7% of patients achieved it within 6 months, 56.3% within 12 months and 71.0% at any point during follow-up after abatacept initiation. Median time to CDAI LDA/remission was 10.2 months. Serious AEs were reported in 2.4% of patients. Common reasons reported by rheumatologists for initiating abatacept were effectiveness/efficacy (52.7%), safety (31.4%) and patient preference (25.3%). Conclusion: In this analysis of patients with ACPA+ and RF+ RA treated with abatacept as a first-line bDMARD in a clinical practice setting, clinical outcomes and remission rates were improved at all time points, providing real-world evidence to further support the use of abatacept in this patient population.

Supplementary Material

File (supplementary materials.docx)

Download
146.11 KB

References

Papers of special note have been highlighted as: • of interest; •• of considerable interest

1.

Kay J, Upchurch KS. ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology 51(Suppl. 6), vi5–vi9 (2012).

2.

Ding Q, Hu W, Wang R et al. Signaling pathways in rheumatoid arthritis: implications for targeted therapy. Signal Transduct. Target. Ther. 8(1), 68 (2023).

3.

Dadoun S, Zeboulon-Ktorza N, Combescure C et al. Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis. Joint Bone Spine 80(1), 29–33 (2013).

4.

Aletaha D, Neogi T, Silman AJ et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 62(9), 2569–2581 (2010).

5.

Smolen JS, Landewe RBM, Bijlsma JWJ et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann. Rheum. Dis. 79(6), 685–699 (2020).

6.

Van Der Helm-Van Mil AHM, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res. Ther. 7(5), R949–958 (2005).

7.

Hecht C, Englbrecht M, Rech J et al. Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA. Ann. Rheum. Dis. 74(12), 2151–2156 (2015).

8.

Sokolove J, Schiff M, Fleischmann R et al. Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial. Ann. Rheum. Dis. 75(4), 709–714 (2016).

9.

Katchamart W, Koolvisoot A, Aromdee E, Chiowchanwesawakit P, Muengchan C. Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis. Rheumatol. Int. 35(10), 1693–1699 (2015).

10.

Humphreys JH, Van Nies JaB, Chipping J et al. Rheumatoid factor and anti-citrullinated protein antibody positivity, but not level, are associated with increased mortality in patients with rheumatoid arthritis: results from two large independent cohorts. Arthritis Res. Ther. 16(6), 483 (2014).

• Compared with single-positive or seronegative status, seropositivity for both anticitrullinated protein antibody (ACPA) and rheumatoid factor (RF) – but not their level – has been associated with increased mortality in early inflammatory rheumatoid arthritis (RA).

11.

Ajeganova S, Humphreys JH, Verheul MK et al. Anticitrullinated protein antibodies and rheumatoid factor are associated with increased mortality but with different causes of death in patients with rheumatoid arthritis: a longitudinal study in three European cohorts. Ann. Rheum. Dis. 75(11), 1924–1932 (2016).

12.

Bonfiglioli KR, De Medeiros Ribeiro AC, Carnieletto AP et al. Extra-articular manifestations of rheumatoid arthritis remain a major challenge: data from a large, multi-centric cohort. Adv. Rheumatol. 63(1), 34 (2023).

13.

Alten R, Mariette X, Flipo RM et al. Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study. Clin. Rheumatol. 41(8), 2361–2373 (2022).

14.

Harrold LR, Bryson J, Lehman T et al. Association between baseline anti-cyclic citrullinated peptide antibodies and 6-month clinical response following abatacept or TNF inhibitor treatment: a real-world analysis of biologic-experienced patients with RA. Rheumatol. Ther. 8(2), 937–953 (2021).

15.

Alten R, Mariette X, Lorenz HM et al. Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study. Clin. Rheumatol. (2019).

16.

Harrold LR, Litman HJ, Connolly SE et al. Effect of anticitrullinated protein antibody status on response to abatacept or antitumor necrosis factor-alpha therapy in patients with rheumatoid arthritis: a US national observational study. J. Rheumatol. 45(1), 32–39 (2018).

17.

Tymms K, Butcher B, Smith T, Littlejohn G. Impact of anti-citrullinated protein antibody on tumor necrosis factor inhibitor or abatacept response in patients with rheumatoid arthritis. Eur. J. Rheumatol. 8(2), 67–72 (2020).

18.

Courvoisier DS, Chatzidionysiou K, Mongin D et al. The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries. Rheumatology (Oxford) 60(2), 820–828 (2021).

19.

Emery P, Gottenberg JE, Rubbert-Roth A et al. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. Ann. Rheum. Dis. 74(6), 979–984 (2015).

20.

Kekow J, Mueller-Ladner U, Schulze-Koops H. Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFalpha blocker failure. Biologics 6, 191–199 (2012).

21.

Burgers LE, Raza K, Van Der Helm-Van Mil AH. Window of opportunity in rheumatoid arthritis - definitions and supporting evidence: from old to new perspectives. RMD Open 5(1), e000870 (2019).

22.

Combe B, Landewe R, Daien CI et al. 2016 update of the EULAR recommendations for the management of early arthritis. Ann. Rheum. Dis. 76(6), 948–959 (2016).

23.

Fraenkel L, Bathon JM, England BR et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 73(7), 1108–1123 (2021).

24.

Malmstrom V, Catrina AI, Klareskog L. The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting. Nat. Rev. Immunol. 17(1), 60–75 (2017).

25.

Schiff M, Weinblatt ME, Valente R et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann. Rheum. Dis. 73(1), 86–94 (2014).

26.

Schiff M, Keiserman M, Codding C et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann. Rheum. Dis. 67(8), 1096–1103 (2008).

27.

Genovese MC, Covarrubias A, Leon G et al. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheumatol. 63(10), 2854–2864 (2011).

28.

Genovese MC, Schiff M, Luggen M et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann. Rheum. Dis. 67(4), 547–554 (2008).

29.

Westhovens R, Kremer J, Emery P et al. Long-term safety and efficacy of abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: a 7-year extended study. Clin. Exp. Rheumatol. 32, 553–562 (2014).

•• In methotrexate methotrexate (MTX)-naive patients with high-risk early RA, combination therapy with MTX and abatacept had higher clinical and radiographic efficacy compared with MTX alone and had a comparably favorable safety profile.

30.

Emery P, Burmester GR, Bykerk VP et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann. Rheum. Dis. 74(1), 19–26 (2015).

31.

Choi S, Ghang B, Jeong S et al. Association of first, second, and third-line bDMARDs and tsDMARD with drug survival among seropositive rheumatoid arthritis patients: cohort study in A real world setting. Semin. Arthritis Rheum. 51(4), 685–691 (2021).

•• Patients with seropositive RA who received tocilizumab, tofacitinib, or abatacept as first- or second-line therapies had lower risk of drug failure risk compared with other DMARDs.

32.

Choy E, Groves L, Sugrue D et al. Outcomes in rheumatoid arthritis patients treated with abatacept: a UK multi-centre observational study. BMC Rheumatol. 5(1), 3 (2021).

•• Patients treated with biologic disease-modifying antirheumatic drugs (bDMARDs) including abatacept had decreased disease activity, and those treated with abatacept in the first- or second-line setting remained on treatment significantly longer versus those receiving other bDMARDs.

33.

Jansen DTSL, Emery P, Smolen JS et al. Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study. RMD Open 4(1), e000564 (2018).

34.

Han X, Lobo F, Broder MS et al. Persistence with early-line abatacept versus tumor necrosis factor-inhibitors for rheumatoid arthritis complicated by poor prognostic factors. J. Health Econ. Outcomes Res. 8(1), 71–78 (2021).

35.

Lalor AF, Brooker JE, Rozbroj T et al. Factors influencing clinician prescribing of disease-modifying anti-rheumatic drugs for inflammatory arthritis: a systematic review and thematic synthesis of qualitative studies. Semin. Arthritis Rheum. 55, 151988 (2022).

36.

Roodenrijs NMT, Van Der Goes MC, Welsing PMJ et al. Non-adherence in difficult-to-treat rheumatoid arthritis from the perspectives of patients and rheumatologists: a concept mapping study. Rheumatology (Oxford) 60(11), 5105–5116 (2021).

37.

Voshaar MJH, Van Den Bemt BJF, Van De Laar M, Van Dulmen AM, Vriezekolk JE. Healthcare professionals' perceptions on barriers and facilitators to DMARD use in rheumatoid arthritis. BMC Health Serv. Res. 22(1), 62 (2022).

38.

International Society for Pharmacoepidemiology. Guidelines for Good Pharmacoepidemiology Practices (GPP). Pharmacoepidemiol. Drug Saf. 25(1), 2–10 (2016).

39.

Berger ML, Sox H, Willke RJ et al. Good practices for real-world data studies of treatment and/or comparative effectiveness: recommendations from the Joint ISPOR–ISPE Special Task Force on Real-World Evidence in Health Care Decision Making. Value Health 20(8), 1003–1008 (2017).

40.

Von Elm E, Altman DG, Egger M et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 4(10), e296 (2007).

41.

World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 277(11), 925–926 (1997).

42.

Salaffi F, Di Carlo M, Farah S, Marotto D, Atzeni F, Sarzi-Puttini P. Rheumatoid arthritis disease activity assessment in routine care: performance of the most widely used composite disease activity indices and patient-reported outcome measures. Acta Biomed. 92(4), e2021238 (2021).

43.

Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin. Exp. Rheumatol. 23(Suppl 39. 5), S100–S108 (2005).

44.

Alten R, Tony HP, Bannert B et al. Subcutaneous abatacept for the treatment of rheumatoid arthritis in routine clinical practice in Germany, Austria, and Switzerland: 2-year retention and efficacy by treatment line and serostatus. Clin. Rheumatol. 42(9), 2321–2334 (2023).

45.

Gottenberg JE, Courvoisier DS, Hernandez MV et al. Brief report: association of rheumatoid factor and anti-citrullinated protein antibody positivity with better effectiveness of abatacept: results from the pan-European registry analysis. Arthritis Rheumatol. 68(6), 1346–1352 (2016).

46.

Azuma T, Misaki K, Kusaoi M et al. Influence of concomitant methotrexate use on the clinical effectiveness, retention, and safety of abatacept in biologic-naive patients with rheumatoid arthritis: post-hoc subgroup analysis of the ORIGAMI study. Mod. Rheumatol. 33(2), 271–278 (2023).

47.

Tamura N, Azuma T, Misaki K et al. Effectiveness and safety of subcutaneous abatacept in biologic-naive RA patients at Week 52: a Japanese multicentre investigational study (ORIGAMI study). Mod. Rheumatol. 32(5), 846–856 (2022).

48.

Götestam Skorpen C, Hoeltzenbein M, Tincani A et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann. Rheum. Dis. 75(5), 795–810 (2016).

49.

Gottenberg JE, Ravaud P, Cantagrel A et al. Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the ‘Orencia and Rheumatoid Arthritis’ registry. Ann. Rheum. Dis. 71(11), 1815–1819 (2012).

50.

Harrold LR, Connolly SE, Wittstock K et al. Baseline anti-citrullinated protein antibody status and response to abatacept or non-TNFi biologic/targeted-synthetic DMARDs: US observational study of patients with RA. Rheumatol. Ther. 9(2), 465–480 (2022).

51.

Gottenberg JE, Courvoisier DS, Hernandez MV et al. Brief report: association of rheumatoid factor and anti-citrullinated protein antibody positivity with better effectiveness of abatacept: results from the pan-European registry analysis. Arthritis Rheumatol. 68(6), 1346–1352 (2016).

52.

Michaud K, Conaghan PG, Park SH et al. Benefits of autoantibody enrichment in early rheumatoid arthritis: analysis of efficacy outcomes in four pooled abatacept trials. Rheumatol. Ther. 10(4), 951–967 (2023).

53.

Poulsen TBG, Damgaard D, Jørgensen MM et al. Identification of potential autoantigens in anti-CCP-positive and anti-CCP-negative rheumatoid arthritis using citrulline-specific protein arrays. Sci. Rep. 11(1), 17300 (2021).

• Patterns of ACPA-recognized proteins may have diagnostic utility for further RA subtyping.

54.

Rigby W, Buckner JH, Louis Bridges S et al. HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA. Arthritis Res. Ther. 23(1), 245 (2021).

55.

Kurowska W, Kuca-Warnawin EH, Radzikowska A, Maslinski W. The role of anti-citrullinated protein antibodies (ACPA) in the pathogenesis of rheumatoid arthritis. Cent. Eur. J. Immunol. 42(4), 390–398 (2017).

56.

Trela M, Perera S, Sheeran T, Rylance P, Nelson PN, Attridge K. Citrullination facilitates cross-reactivity of rheumatoid factor with non-IgG1 Fc epitopes in rheumatoid arthritis. Sci. Rep. 9(1), 12068 (2019).

57.

Aripova N, Kremer JM, Pappas DA et al. Anti-citrullinated protein antibody profiles predict changes in disease activity in patients with rheumatoid arthritis initiating biologics. Rheumatology (Oxford) (2023).

58.

Hirose W, Harigai M, Amano K et al. Impact of the HLA-DRB1 shared epitope on responses to treatment with tofacitinib or abatacept in patients with rheumatoid arthritis. Arthritis Res. Ther. 23(1), 228 (2021).

59.

Fernandes-Cerqueira C, Ossipova E, Gunasekera S et al. Targeting of anti-citrullinated protein/peptide antibodies in rheumatoid arthritis using peptides mimicking endogenously citrullinated fibrinogen antigens. Arthritis Res. Ther. 17(1), 155 (2015).

•• Two kinds of chains originating from fibrinogen α can prevent pathogenic binding of ACPA with CCP, and targeting ACPAs may reduce bone destruction and alleviate clinical RA symptoms.

60.

Wunderlich C, Oliviera I, Figueiredo CP, Rech J, Schett G. Effects of DMARDs on citrullinated peptide autoantibody levels in RA patients – a longitudinal analysis. Semin. Arthritis Rheum. 46(6), 709–714 (2017).

|